Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Marco Gabriele Raddi"'
Autor:
Davide Leardini, Sara Cerasi, Francesco Baccelli, Francesca Gottardi, Edoardo Muratore, Krisztián Miklós Kállay, Paula Kjollerstrom, Sara Batalha, Elisa Rumi, Valeria Santini, Marco Gabriele Raddi, Anupama Rao, Ana Rio-Machin, Riccardo Masetti
Publikováno v:
EJC Paediatric Oncology, Vol 2, Iss , Pp 100042- (2023)
Externí odkaz:
https://doaj.org/article/c21ea3142b424e55bca227fb64e96b5e
Autor:
Enrico Attardi, Immacolata Andolfo, Roberta Russo, Lucia Tiberi, Marco Gabriele Raddi, Barbara Eleni Rosato, Roberta Marra, Daniela Formicola, Federica Del Giudice, Alice Brogi, Angela Consagra, Cristina Amato, Alessandro Sanna, Rosangela Artuso, Achille Iolascon, Valeria Santini
Publikováno v:
American Journal of Hematology. 98
Autor:
Angela Consagra, Alessandro Sanna, Marco Gabriele Raddi, Luca Rigodanza, Enrico Attardi, Cristina Amato, Margherita Cassari, Elena Tofacchi, Giorgio Mattiuz, Sven de Pourcq, Valeria Santini
Publikováno v:
Blood. 140:11738-11739
Autor:
Alessandro Sanna, Angela Consagra, Rosangela Artuso, Valeria Santini, Alice Brogi, Lucia Tiberi, Marco Gabriele Raddi, Enrico Attardi, Achille Iolascon, Cristina Amato, Daniela Formicola, Immacolata Andolfo, Roberta Russo
Publikováno v:
Blood. 138:1528-1528
BACKGROUND: Anemia is the most frequent cytopenia in myelodysplastic syndromes (MDS), neoplastic diseases characterized by ineffective hematopoiesis and bone marrow dysplasia. MDS usually affect elderly individuals (median age in Italy 74 years), and
Autor:
Marco Gabriele Raddi, Enrico Attardi, Angela Consagra, Cristina Amato, Valeria Santini, Alice Brogi, Erico Masala, Benedetta Peruzzi, Sara Bencini, Roberto Caporale, Alessandro Sanna
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S228
Autor:
Marco Gabriele Raddi, Erico Masala, Angela Consagra, Benedetta Peruzzi, Roberto Caporale, Cristina Amato, Enrico Attardi, Valeria Santini, Alice Brogi, Sara Bencini, Alessandro Sanna
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S344
Context: Standard treatment of anemia in lower-risk myelodysplastic syndromes (LR-MDS) is based on erythropoietic-stimulating agents (ESAs), but some patients are primary refractory (PR) or lose response (secondary refractory, SR). High serum erythro